In Vitro Bacterial Invasion Assay: Principle, Methodology, and Applications

The in vitro bacterial invasion assay is a cell-based test that quantifies the ability of bacteria to adhere to and invade cultured mammalian cells, providing essential data for pathogen virulence assessment, probiotic characterization, and anti-infective product development. This article explains the testing principle, sample types, methodology, quality controls, and typical applications of the assay as performed in accredited third-party laboratories.

Technical Overview

The in vitro bacterial invasion assay, also known as the antibiotic protection assay or gentamicin protection assay, is a quantitative cell culture method used to evaluate the capacity of bacteria to adhere to, penetrate, and survive inside cultured host cells. In this assay, a monolayer of mammalian cells is infected with a standardized bacterial suspension at a defined multiplicity of infection (MOI). After an established incubation period, extracellular bacteria are eliminated using a cell-impermeable antibiotic, typically gentamicin. The host cells are then lysed with a mild detergent, such as Triton X-100 or sodium deoxycholate, to release intracellular bacteria, which are serially diluted, plated on suitable agar, and enumerated as colony-forming units (CFU). The invasion rate is calculated as the percentage of the inoculum that survives antibiotic treatment and is recovered from within the cells.

The assay is routinely performed under Biosafety Level 2 (BSL-2) conditions in accordance with the WHO Laboratory Biosafety Manual, with general microbiological operations following the guidance of ISO 7218. Testing laboratories typically conduct the assay using internally validated standard operating procedures under an ISO/IEC 17025 quality management system, ensuring traceable, reproducible, and quantitative results.

Testing Samples

Bacterial Isolates and Strains

Common test organisms include foodborne and clinical pathogens such as Salmonella enterica, Listeria monocytogenes, Shigella spp., Yersinia enterocolitica, Staphylococcus aureus, and invasive Escherichia coli pathotypes. The assay is also applied to attenuated or genetically engineered strains, live vaccine candidates, and probiotic strains of Lactobacillus and Bifidobacterium, for which adhesion is characterized and invasiveness is confirmed to be absent as part of safety assessment.

Test Compounds and Products

Antimicrobial agents, bacteriocins, plant extracts, immunoglobulin preparations, surface coatings, and functional food ingredients can be evaluated for their ability to inhibit bacterial adhesion or invasion. Probiotic finished products and fermented foods are also submitted for strain-level adhesion and competitive exclusion testing.

Host Cell Models

Selection of the host cell line depends on the infection site being modeled. Frequently used lines include human intestinal epithelial cells (Caco-2, HT-29, HCT-8), epithelial carcinoma cells (HeLa, Hep-2), lung epithelial cells (A549), and macrophage-like cells (RAW 264.7) for intracellular survival studies. Veterinary research may employ species-specific lines such as MAC-T or PK-15.

Testing Items

• Bacterial adhesion assay: quantification of cell-associated bacteria without antibiotic treatment, expressed as adhesion rate or bacteria per host cell.
• Bacterial invasion assay: quantification of intracellular bacteria after antibiotic protection, expressed as invasion rate or invasion percentage.
• Intracellular survival and replication assay: time-course enumeration of intracellular CFU to assess replication within host cells.
• Competitive exclusion testing: evaluation of probiotic strains or test compounds that block pathogen adhesion and invasion.
• Inhibition dose-response testing: determination of the concentration of a test substance that reduces invasion by 50 percent (IC50).
• Host cell cytotoxicity assessment: complementary viability assays, such as MTT or LDH release, to distinguish reduced invasion from host cell death.

Testing Methods

The standard workflow of the gentamicin protection assay is summarized below:

• Host cells are cultured to a confluent, differentiated monolayer in multi-well plates, typically for 24 to 72 hours depending on the cell line.
• Bacterial strains are grown to logarithmic phase, washed, and standardized by optical density or plate count to achieve the target MOI, commonly between 10 and 100 bacteria per host cell.
• The monolayer is inoculated and incubated for a defined infection period, usually 1 to 2 hours, to allow adhesion and internalization.
• Extracellular bacteria are killed by treatment with gentamicin at a validated bactericidal concentration, typically 50 to 200 micrograms per milliliter, for 1 to 2 hours.
• Cells are washed and lysed with 0.1 percent Triton X-100 or an equivalent mild detergent to release intracellular bacteria.
• Lysates are serially diluted, plated on appropriate agar media, and incubated for CFU enumeration.
• Invasion rate is calculated as intracellular CFU divided by the inoculum CFU, multiplied by 100; adhesion rate is calculated in parallel wells without antibiotic treatment.

Quality controls are essential for valid interpretation. Each experiment includes a known invasive positive-control strain, a non-invasive negative-control strain, cell-only and bacteria-only sterility controls, and verification that the antibiotic concentration fully inactivates extracellular bacteria. All conditions are tested in replicate, and results are accepted only when control strains perform within historical limits. Confirmatory techniques, including immunofluorescence microscopy, differential staining, or quantitative PCR, may be used to visualize or independently verify intracellular localization.

Applications

• Food safety and virulence profiling: comparative invasiveness assessment of pathogen isolates from food, environmental, or clinical sources to support risk characterization and root-cause investigations.
• Probiotic and functional food development: demonstration of adhesion capacity and non-invasiveness of candidate strains, and documentation of competitive exclusion against enteric pathogens.
• Anti-infective research and screening: identification of compounds, bacteriocins, or biologics that reduce bacterial adhesion or intracellular invasion.
• Vaccine and live biotherapeutic research: phenotypic confirmation of attenuation in engineered or mutated strains intended for human or veterinary use.
• Veterinary and aquaculture microbiology: virulence evaluation of animal pathogens in species-relevant cell lines.
• Regulatory and scientific documentation: generation of quantitative data packages for product dossiers, patent filings, and peer-reviewed publication.

FAQ

What is the core principle of the in vitro bacterial invasion assay?

The assay exploits the fact that gentamicin and similar aminoglycoside antibiotics cannot penetrate intact mammalian cells. After infection, extracellular bacteria are killed while internalized bacteria are protected. Lysis of the host cells releases the intracellular bacteria, which are then quantified by plate counting to determine the invasion rate.

Which bacterial species can be tested?

Most facultative intracellular pathogens can be evaluated, including Salmonella, Listeria monocytogenes, Shigella, Yersinia, Staphylococcus aureus, and invasive E. coli. Obligate intracellular organisms and agents requiring Biosafety Level 3 containment require dedicated facilities and prior risk assessment.

How are the results reported?

Reports typically include adhesion rate, invasion rate expressed as a percentage of the inoculum, CFU per well or per host cell, raw enumeration data, control strain performance, and the experimental parameters such as MOI, infection time, and antibiotic concentration.

How long does the test take?

A standard assay, including cell culture preparation, infection, and enumeration, is generally completed within one to two weeks. Studies involving dose-response curves, time courses, or multiple strains and cell lines may require additional time.

What sample preparation is required from the client?

Clients should provide pure, viable bacterial isolates on agar slants or frozen stocks together with strain information, intended cell line, and the desired test items. Accredited third-party laboratories can also perform strain revival, identification confirmation, and culture standardization as part of the service.

Which standards govern this assay?

There is no single international standard dedicated to bacterial invasion testing. Laboratories apply internally validated procedures consistent with ISO/IEC 17025 quality requirements, ISO 7218 microbiological guidance, and WHO biosafety recommendations, with method validation data available upon request.